Fifty-four patients with KRAS-mutated T3/4 and/or N1/2M0 locally advanced rectal cancers were included and treated with neoadjuvant treatment with radiotherapy (45 Gy in 25 fractions over 5 weeks) and capecitabine 825 mg/m2 twice daily plus sorafenib 400 mg/d. This evidence concerns the gene KRAS and rectal cancer.